Nanologica AB NICA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 33.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nanologica AB develops and manufactures nanoporous silica particles for life science applications. It focuses on two areas: Drug Development and Chromatography. The company's drug delivery platforms are NLAB Spiro and NLAB Silica, which focus on producing medicines for the benefit of patients. Its geographical segments are Sweden, China, India, the United States, and the Rest of the world.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 16
- Website
- https://www.nanologica.com
Comparables
Valuation
|
Metric
|
NICA
|
MCAP
|
BICO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 38.25 | — |
Price/Book Value | 19.15 | 6.60 | 1.02 |
Price/Sales | 33.96 | 4.35 | 1.42 |
Price/Cash Flow | — | 23.29 | — |
Price/Earnings
NICA
MCAP
BICO
Financial Strength
|
Metric
|
NICA
|
MCAP
|
BICO
|
|---|---|---|---|
Quick Ratio | 1.82 | 1.35 | 1.74 |
Current Ratio | 1.96 | 2.23 | 2.52 |
Interest Coverage | −13.13 | 14.80 | −20.02 |
Quick Ratio
NICA
MCAP
BICO
Profitability
|
Metric
|
NICA
|
MCAP
|
BICO
|
|---|---|---|---|
Return on Assets (Normalized) | −57.14% | 10.75% | −4.62% |
Return on Equity (Normalized) | −214.40% | 17.72% | −7.26% |
Return on Invested Capital (Normalized) | −188.42% | 13.91% | −6.72% |
Return on Assets
NICA
MCAP
BICO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dvzqpfhyr | Vwqbh | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cnmrhvjfz | Wrttgqm | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yhlvyrfn | Dgbssc | $105.3 Bil | |
MRNA
| Moderna Inc | Pywcxqdzj | Qcmv | $47.0 Bil | |
ARGX
| argenx SE ADR | Mxfhnylgg | Ldwh | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wxxxdlzsp | Qdntc | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cmnjnzlj | Rwrbffm | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yvlxsbp | Jmlbty | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sxgfmyndfq | Vqrvgt | $12.7 Bil | |
INCY
| Incyte Corp | Qzyksnlsx | Pttrx | $12.0 Bil |